克拉斯
医学
突变
癌症研究
癌症
GTP'
细胞
肺癌
内科学
生物
遗传学
生物化学
结直肠癌
基因
酶
作者
Shan-Shan Lu,H. Jian,Yu Zhang,Z. Song,Y. Zhao,P. Wang,L. Jiang,Y. Gong,J. Zhou,X. Dong,N. Yang,J. Fang,Wuwei Zhuang,S. Cang,R. Ma,J. Shi,Peipei Wu,J. Lu,Zhiwei Xiang,Z. Shi,L. Zhang,Y. Wang
标识
DOI:10.1016/j.jtho.2022.07.026
摘要
KRAS G12C mutation acts as a key oncogenic driver occurring in approximately 15% of non-small cell lung cancer (NSCLC). An activating KRAS mutation (for example, G12C mutation) results in KRAS protein accumulated in the GTP-bound, active form, which is believed to drive the abnormal growth of cancer cells in multiple tumor types. D-1553 is an orally bioavailable inhibitor of KRAS G12C that selectively and irreversibly binds KRAS G12C mutated protein in an inactive GDP-bound state.
科研通智能强力驱动
Strongly Powered by AbleSci AI